Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

 09 Mar 2026 12:33 PM

Lupin: Company Reports Cargo Movement Affected Due To Container Delays At Ports From Europe And The Middle East.-Cnbc TV18

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

 09 Mar 2026 12:35 PM

Lupin: Higher Oil Prices May Cause Increase in Solvent Costs

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

 09 Mar 2026 09:12 AM

Lupin: Morgan Stanley maintains Equal-Weight on Lupin Limited with Target Price Rs 2,386, noting the USFDA Form 483 with only two observations indicates manageable compliance risk, while FY26 is expected to deliver a second consecutive year of strong earnings growth.

Lupin: USFDA Inspection At Lupin's Ankleshwar Plant Ends With Two Observations.

 09 Mar 2026 08:45 AM

Lupin: USFDA Inspection At Lupin's Ankleshwar Plant Ends With Two Observations.

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

 05 Mar 2026 09:05 AM

Lupin: Goldman Sachs on Lupin Neutral, Target Price Rs 2275

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Co's Financials

 02 Mar 2026 09:11 PM

Lupin: Maharashtra GST Department Finishes Inspection With No Negative Findings; No Effect On Co's Financials

Lupin: Nanomi B.V. Delays Purchase of Visufarma B.V.; Deal Now Anticipated to Finalize in April 2026, Awaiting Required Approvals

 27 Feb 2026 07:45 PM

Lupin: Nanomi B.V. Delays Purchase of Visufarma B.V.; Deal Now Anticipated to Finalize in April 2026, Awaiting Required Approvals

Lupin: Gets Satisfactory Establishment Inspection Report From US FDA For Goa Facility, With Voluntary Action Indicated.

 27 Feb 2026 01:01 PM

Lupin: Gets Satisfactory Establishment Inspection Report From US FDA For Goa Facility, With Voluntary Action Indicated.

Lupin: Company Gets FDA Approval For Brivaracetam Oral Solution, Estimated U.S. Sales Of $135 Million

 24 Feb 2026 07:21 PM

Lupin: Company Gets FDA Approval For Brivaracetam Oral Solution, Estimated U.S. Sales Of $135 Million

Lupin: Gets European Commission Approval For Biosimilar Ranibizumab; Sandoz To Market Product In EU, Excluding Germany; Confirms Company's Dedication To Affordable Biologic Treatments

 23 Feb 2026 03:28 PM

Lupin: Gets European Commission Approval For Biosimilar Ranibizumab; Sandoz To Market Product In EU, Excluding Germany; Confirms Company's Dedication To Affordable Biologic Treatments

Lupin: USFDA Inspects Lupin's Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

 19 Feb 2026 10:59 AM

Lupin: USFDA Inspects Lupin's Largest Goa Facility, Raises Concerns About Quality Control Issues - CNBC TV18

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada

 16 Feb 2026 05:41 PM

Lupin: Company Partners With Spektus To Distribute New Antidepressant Deslaflex In Canada

Citi maintains 'Buy' ratings on Lupin, hikes target price to Rs 2,540.

 16 Feb 2026 09:00 AM

Citi maintains 'Buy' ratings on Lupin, hikes target price to Rs 2,540.

MorganStanley's call on Lupin: Equal-weight call, target price at ₹2,386/sh

 16 Feb 2026 09:02 AM

MorganStanley's call on Lupin: Equal-weight call, target price at ₹2,386/sh

Nomura maintains buy on Lupin with a target price of ₹2,580

 16 Feb 2026 09:03 AM

Nomura maintains buy on Lupin with a target price of ₹2,580

Lupin: Company Raises Full-Year FY26 EBITDA Margin Guidance To 27%-28% From 25%-26%, Though Q4 Margins May Be Affected By Higher R&D Costs And Lower PLI Income. For FY27, The Company Predicts EBITDA Margins At 24%-25% While Expecting Steady Revenue Growth And A Focus On Costs Despite Risks From Product Competition And Rising R&D Expenses.

 16 Feb 2026 08:38 AM

Lupin: Company Raises Full-Year FY26 EBITDA Margin Guidance To 27%-28% From 25%-26%, Though Q4 Margins May Be Affected By Higher R&D Costs And Lower PLI Income. For FY27, The Company Predicts EBITDA Margins At 24%-25% While Expecting Steady Revenue Growth And A Focus On Costs Despite Risks From Product Competition And Rising R&D Expenses.

Lupin: India Formulations Business Expected to Be 1.2X to 1.3X Ahead of Indian Pharmaceutical Market, Boosted by Strong Sales and 80+ New Products. Company Plans to Invest $250 Million to $300 Million in Specialty Assets, Focusing on Acquisitions in Developed Markets.

 16 Feb 2026 08:38 AM

Lupin: India Formulations Business Expected to Be 1.2X to 1.3X Ahead of Indian Pharmaceutical Market, Boosted by Strong Sales and 80+ New Products. Company Plans to Invest $250 Million to $300 Million in Specialty Assets, Focusing on Acquisitions in Developed Markets.

Lupin: Management Anticipates Double-Digit Growth of 20% to 30% in India, Outpacing Market's 7% to 8% Annual Growth. Key Growth Factors Include Resolved Past Exclusivities, Insulin Opportunities, and Upcoming Semaglutide Launch.

 16 Feb 2026 08:38 AM

Lupin: Management Anticipates Double-Digit Growth of 20% to 30% in India, Outpacing Market's 7% to 8% Annual Growth. Key Growth Factors Include Resolved Past Exclusivities, Insulin Opportunities, and Upcoming Semaglutide Launch.

Lupin: Company Plans First 505(B)(2) Products Launch in FY27 and Exclusive XYWAV Product Launch in FY29. Injectable Portfolio, Including Dalbavancin, Eribulin, and Iron Sucrose, Expected to Exceed $100 Million in Three Years.

 16 Feb 2026 08:38 AM

Lupin: Company Plans First 505(B)(2) Products Launch in FY27 and Exclusive XYWAV Product Launch in FY29. Injectable Portfolio, Including Dalbavancin, Eribulin, and Iron Sucrose, Expected to Exceed $100 Million in Three Years.

Lupin: Company Increases FY26 Margin Guidance From 25-26% To 27-28% - CNBCTv18

 13 Feb 2026 12:31 PM

Lupin: Company Increases FY26 Margin Guidance From 25-26% To 27-28% - CNBCTv18